CORT · Corcept Therapeutics Incorporated · Stock research

Current Thesis

The post-CRL redemption trade is long over, but the tape re-accelerated instead of dying in a base. Shares round-tripped from the $28.66 CRL low (2025-12-30) to a $91 high on the 2026-05-29 ASCO overall-survival print, then cleared that shelf and pressed to fresh 52-week highs near $92 in early July (P/E ~228, ~$9.86B cap). Two live legs drive it: the Lifyorli (relacorilant) platinum-resistant ovarian-cancer launch FDA-approved early on 2026-03-25, NCCN preferred regimen since April now ramping into its first full-quarter print around 2026-08-05; and the Cushing's relacorilant resubmission (physically refiled 2026-06-17, six-month review, PDUFA ~December 2026) that re-opens second-approval optionality with no new trials required. The narrative is intact and multi-legged. The problem is the entry: buying $92 is +56% above the 50-day (~$59), past the $88.83 consensus target, with an insider Form 144 filed 2026-07-07 and the next hard catalyst an earnings print the run has already front-run. A stretched breakout into a binary, not a fat pitch better bought on a pullback than chased at 228x.

Bullish and bearish views on Corcept Therapeutics Incorporated

The model's bull view on Corcept Therapeutics Incorporated (CORT), in brief: Lifyorli launch is live and ramping. FDA approved relacorilant + nab-paclitaxel for platinum-resistant ovarian cancer on 2026-03-25, ahead of the 2026-07-11 PDUFA the first-in-class selective glucocorticoid-receptor antagonist, no biomarker testing gating use. NCCN added it as a… The bear view: The valuation front-ran the story. ~228x earnings and a ~$9.86B cap at $92 already discount a Cushing's approval that has not been granted and an oncology ramp with one reported quarter behind it. Current price sits ABOVE the $88.83 consensus target. Q1 was a miss (2026-04-30).… Both cases follow in full.

Bull Case

• Lifyorli launch is live and ramping. FDA approved relacorilant + nab-paclitaxel for platinum-resistant ovarian cancer on 2026-03-25, ahead of the 2026-07-11 PDUFA the first-in-class selective glucocorticoid-receptor antagonist, no biomarker testing gating use. NCCN added it as a preferred regimen in April 2026. List price $37,900 per 28-day cycle layers specialty-oncology economics onto the Korlym endocrine base.
• ASCO OS data de-risked the drug (2026-05-29). ROSELLA: 35% death-risk reduction, HR 0.65, p=0.0004, median OS 16.0 vs 11.9 months, benefit across all subgroups including recent-taxane patients; shares popped +15.4%.
• Cushing's resubmission restarts the FDA clock (2026-06-17). NDA refiled with additional analyses of the original data, no new trials required; six-month review implies a PDUFA around December 2026 a second-approval option not in the base business.
• Guidance raised (2026-04-30). FY2026 revenue guide lifted to $950M–$1.05B from $900M–$1.0B, implying a back-half oncology ramp; management frames a path past $1B U.S. revenue by decade-end.
• Sell-side targets bracket the tape. Canaccord Genuity Buy, PT $135 (2026-05-28); HC Wainwright Buy, PT $95 (2026-05-28). YTD +164%; 27.8% one-year gain.
• Institutional interest flagged. CORT surfaced on whale-alert health-care option screens on 2026-06-09 and 2026-06-29, consistent with active positioning around the refile and the launch quarter.
• Funded through the catalyst. Cash and investments $515.4M at 2026-03-31; no financing overhang into the Cushing's decision.

Bear Case

• The valuation front-ran the story. ~228x earnings and a ~$9.86B cap at $92 already discount a Cushing's approval that has not been granted and an oncology ramp with one reported quarter behind it. Current price sits ABOVE the $88.83 consensus target.
• Q1 was a miss (2026-04-30). Revenue $164.9M (+4.9% YoY) marks a hard deceleration from prior double-digit growth, and the quarter swung to a $31.8M net LOSS from +$20.5M net income a year earlier on launch spend and legal costs.
• Chart is extended, not building a base. At $92 the stock is roughly +56% above both the 50-day (~$58.94) and 200-day (~$59.96) the stretched-above-MA condition that mean-reverts.
• Insider supply near the high. A Form 144 proposed-sale notice was filed 2026-07-07 with shares in the low-$90s.
• Cushing's remains binary. The prior CRL (2025-12-30) cited a need for additional evidence of effectiveness; the resubmission answers with analyses rather than a new trial a refuse-to-file or second CRL is a live tail into ~December.
• Litigation overhang. A securities class action and an amended former-employee complaint (disclosed 2026-06-03) recur as headline risk on strength.

Setup & Price Structure

Price ~$91.88 (2026-07-10), inside an early-July range of $91.61–$94.04, pressing into new 52-week-high territory above the prior $91 ASCO high; the all-time high is $117.33 (2025-03-31). The June low-$70s consolidation resolved higher the name broke out of the ~$74–82 shelf in late June and has held the low-$90s for two weeks. Momentum is intact but the extension is extreme: +56% above the 50-day (~$59) and 200-day (~$60), with RSI in overbought territory. The rising 20-EMA sits well below current price near the breakout shelf; first real support on a pullback is the late-June breakout zone (~$80), then the June base (~$74), then the MA cluster near $58–60. For a momentum book, strength at new highs is confirmation yet a fresh entry +56% above the mean, past consensus targets, with a binary earnings print ~24 days out, is chasing rather than positioning. The cleaner entry is a pullback to the breakout shelf / rising 20-EMA rather than the $92 print, and this is a single-name biotech binary, not a cluster-confirmed theme leader that earns a chase on extension.

Catalyst Calendar (next 30 days)

• ~2026-08-05 (est., confirm) Q2 2026 earnings. The first full quarter of the Lifyorli launch; the binary the June–July rally has front-run. A 3-day pre-print blackout applies before sizing. Watch oncology revenue ramp, FY guide, prescriber count, and net-loss trajectory.

Elapsed catalysts

• ~2026-07-17 (est.) Cushing's resubmission acceptance window. Roughly 30 days from the 2026-06-17 refile, the FDA typically confirms review classification (Class 2 / six-month); an accept vs refuse-to-file signal, if disclosed, is a soft catalyst. _(passed 2d ago)_
• No relacorilant PDUFA in the window. The 2026-07-11 ovarian-cancer action date is moot approval came early on 2026-03-25. The Cushing's PDUFA sits ~December 2026, outside 30 days. _(passed 8d ago)_

What Would Change Our Mind

• Bullish confirmation: a strong Q2 print around 2026-08-05 oncology revenue beating the implied launch ramp, FY guide raised again, an expanding prescriber base would validate the acceleration and justify pressing through the extension; a clean FDA acceptance of the Cushing's resubmission would firm the December option.
• Thesis break: a weekly close below $80 loses the late-June breakout shelf and the rising 20-EMA that define this leg, turning the breakout into a failed move back toward the $74 base. A refuse-to-file or second CRL on the 2026-06-17 Cushing's resubmission, or a Q2 revenue miss / guide cut around 2026-08-05, would confirm the fundamental leg has cracked. A third straight quarter of sub-10% YoY revenue growth with continued net losses re-rates the multiple lower.

Correlation Notes

Idiosyncratic single-drug biotech the tape trades on Lifyorli launch data and the Cushing's regulatory path rather than a sector cluster, so there is no peer-breakout confirmation to lean on. Loosely correlated to small/mid-cap biotech risk appetite (XBI) and to the broad rate/risk regime, but binary drug and FDA events dominate beta on catalyst days. Read-through names are thin: SGRA / cortisol-modulation is essentially a single-company franchise, so peer signals are weak and the position carries full single-name, single-catalyst risk. Sizing should reflect that the next hard catalyst is an earnings binary in ~3.5 weeks and the fundamental re-rating event (Cushing's PDUFA) is ~5 months out.